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Abstract This review aims at presenting state-of-the-art
knowledge on the composition and functions of the endothe-
lial glycocalyx. The endothelial glycocalyx is a network of
membrane-bound proteoglycans and glycoproteins, covering
the endothelium luminally. Both endothelium- and plasma-
derived soluble molecules integrate into this mesh. Over the
past decade, insight has been gained into the role of the
glycocalyx in vascular physiology and pathology, including
mechanotransduction, hemostasis, signaling, and blood cell–
vessel wall interactions. The contribution of the glycocalyx to
diabetes, ischemia/reperfusion, and atherosclerosis is also
reviewed. Experimental data from the micro- and macro-
circulation alludes at a vasculoprotective role for the glyco-
calyx. Assessing this possible role of the endothelial
glycocalyxrequiresreliablevisualizationofthisdelicatelayer,
whichisagreatchallenge.Anoverviewisgivenofthevarious
ways in which the endothelial glycocalyx has been visualized
up to now, including first data from two-photon microscopic
imaging.
Keywords Endothelialglycocalyx.Endothelialsurface
layer.Heparansulfate.Hyaluronicacid.Vasculardisease.
Opticalimaging.Two-photonmicroscopy
Introduction
The endothelial glycocalyx was already visualized some
40 years ago by Luft using electron microscopy [66]. Still,
relatively little is known of the composition and function of
this layer. Over the past decades, it has been increasingly
appreciated as an important factor in vascular physiology
and pathology, as described in 2000 in a review by Pries et
al. [86] and in other, more recent reviews [4, 74]. The
interest in the (patho)physiological role of the glycocalyx
started with the observation of low and variable capillary
tube hematocrit, which depended on the level of metabolic
and pharmacological activation of the vascular system [51,
52, 63, 83, 101]. The relation between metabolic and
agonist-induced increases in red blood cell velocity on the
one hand and tube hematocrit on the other could partly be
explained by plasma skimming as direct continuation of the
Fåhraeus effect [83]. However, this relation dissociated
upon local treatment of the microvessels with heparinase,
an enzyme which breaks down heparan sulfates in the
glycocalyx [17]. This finding was in agreement with
theoretical estimates predicting a 1.2-μm thick slow-
moving plasma layer over the endothelium [51]. In vivo
studies have revealed the glycocalyx in muscle capillaries to
be a layer of about 0.5 μm thick, covering endothelial cells
and determining luminal domains for macromolecules, red
and white blood cells [129]. More recent studies indicate that
glycocalyx thickness increases with vascular diameter, at
least in the arterial system, ranging from 2 to 3 μmi ns m a l l
arteries [125]t o4 . 5μm in carotid arteries [67].
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physiological roles for the endothelial glycocalyx; in
addition to modulating capillary red blood cell filling, the
glycocalyx may affect many other (dys)functions of the
vascular system. Whereas the vascular endothelium is
currently believed to be actively involved “in every
pathology presenting vascular projections” [28], the same
saying might well prove true for the glycocalyx. Assessing
this possible involvement of the endothelial glycocalyx
requires reliable visualization of this delicate layer, which is
a great challenge. This review provides basic insight into
the present knowledge of composition and functions of the
endothelial glycocalyx and gives an overview of the various
ways in which it has been visualized up to now.
Composition
The endothelial glycocalyx is a carbohydrate-rich layer
lining the vascular endothelium. It is considered to be
connected to the endothelium through several “backbone”
molecules, mainly proteoglycans and also glycoproteins.
These form a network in which soluble molecules, either
plasma- or endothelium-derived, are incorporated. More
luminally, the glycocalyx is formed by soluble plasma
components, linked to each other in a direct way or via
soluble proteoglycans and/or glycosaminoglycans (which
will be discussed below). A dynamic equilibrium exists
between this layer of soluble components and the flowing
blood, continuously affecting composition and thickness of
the glycocalyx. Furthermore, the glycocalyx suffers from
enzymatic or shear-induced shedding. The dynamic balance
between biosynthesis and shedding makes it hard to define
the glycocalyx geometrically [62]. The composition of the
membrane-bound mesh of proteoglycans, glycoproteins,
and glycosaminoglycans and the composition of associated
plasma proteins and soluble glycosaminoglycans cannot be
viewed as a static picture. Instead, the layer as a whole—
also known as endothelial surface layer (ESL) [86]—is very
dynamic, with membrane-bound molecules being constant-
ly replaced and no distinct boundary between locally
synthesized and associated elements; membrane-bound
hyaluronan may reach lengths of >1 μm. Direct visualiza-
tion techniques (see section on Visualization techniques)
fail to demonstrate clear compositional differences within
the glycocalyx, from endothelial membrane towards vascu-
lar lumen, but rather indicate that the endothelial glyco-
calyx resembles an intricate, self-assembling 3D mesh of
various polysaccharides. Enzymatic removal of any of its
constituents dramatically affects glycocalyx properties,
which exemplifies the importance of considering the
synergetic interaction of all glycocalyx constituents as a
whole. In this review we will, therefore, use the term
(endothelial) glycocalyx for the total layer (Fig. 1) and be as
specific as possible when addressing its various elements.
Below, state-of-the-art knowledge on the various com-
ponents of the endothelial glycocalyx will be provided.
Although many molecules have been identified as being
part of the glycocalyx, information on their distribution is
still scarce; if present, such knowledge was mostly obtained
indirectly and nonquantitatively.
Proteoglycans
Proteoglycans are generally considered to function as the
most important “backbone” molecules of the glycocalyx.
They consist of a core protein to which one or more
glycosaminoglycan chains are linked. There is a notable
variation among the proteoglycan core proteins with regard
to their size, number of attached glycosaminoglycan chains,
and whether or not they are bound to the cell membrane
(Table 1). The core protein groups of syndecans (n=4) and
glypicans (n=6) have a firm connection to the cell
membrane via a membrane-spanning domain (syndecans)
or a glycosylphosphatidylinositol anchor (glypicans) [12,
25]. The other proteoglycans, such as mimecan, perlecan,
and biglycan, are secreted after their assembly and
glycosaminoglycan chain modification [44, 50]. This leads
to production of soluble proteoglycans, which reside in the
glycocalyx or diffuse into the blood stream.
Proteoglycans are promiscuous in their binding of
glycosaminoglycan chains, meaning that one core protein
can contain different types of glycosaminoglycan chains.
The proportion of the various chains may change under
different circumstances and stimuli [89]. Therefore, naming
of proteoglycans after one type of glycosaminoglycan is
somewhat deluding. For example, syndecan-1 proteoglycan
is often addressed as a heparan sulfate proteoglycan, while
in fact, it usually contains similar numbers of heparan
sulfate and chondroitin sulfate chains [70].
There are five types of glycosaminoglycan chains:
heparan sulfate, chondroitin sulfate, dermatan sulfate,
keratan sulfate, and hyaluronan (or hyaluronic acid). They
are linear polymers of disaccharides with variable lengths
that are modified by sulfation and/or (de)acetylation to a
variable extent. The disaccharides are each composed of a
uronic acid and a hexosamine; classification of the
glycosaminoglycans depends on which uronic acid or
hexosamine is incorporated and on the pattern of sulfation
(Table 2). Each of the five glycosaminoglycans has been
investigated and reviewed extensively [22, 27, 57, 58, 114].
Dermatan sulfate is often regarded as a separate class of
glycosaminoglycans, although it actually is type B chon-
droitin sulfate. The difference between the two is possible
epimerization of the glucuronic acids into iduronic acids in
dermatan sulfate, which has important consequences for
346 Pflugers Arch - Eur J Physiol (2007) 454:345–359functionality. Whenever possible, we will try to separate the
two as precisely as possible; elsewhere, they will be
referred to as chondroitin sulfate/dermatan sulfate.
In vasculature, heparan sulfate proteoglycans represent
roughly 50–90% of the total amount of proteoglycans
present in the glycocalyx [43, 86]. However, this figure is
variable, as the expression of proteoglycans by endothelial
cells depends on various stimuli. Syndecans, for example,
have a tightly regulated expression pattern which varies
with endothelial cell activation or stimulation with different
chemokines [119]. The second most common glycosami-
noglycan in the endothelial cell glycocalyx is chondroitin
sulfate/dermatan sulfate. The presence of heparan sulfate
and chondroitin sulfate is reported to have a typical ratio of
4:1 for the vascular endothelium [70, 90]. Expression of
keratan sulfate glycosaminoglycans in vasculature and its
importance in (patho)physiology is less well understood.
Another important glycosaminoglycan in the glycocalyx is
hyaluronan. This long polymeric molecule (up to 10
4 kDa)
differs from other glycosaminoglycans in that it is not
linked to a core protein. Its exact link to the cell membrane
is unknown, but it can be bound to the receptor CD44 [72].
Alternatively, hyaluronan may be attached to its assembly
proteins, the hyaluronan synthases [135], which are located
Fig. 1 Schematic representation of the endothelial glycocalyx,
showing its main components. Left: The endothelial glycocalyx can
be observed in vivo as a red blood cell exclusion zone, located on the
luminal side of the vascular endothelium. It consists of membrane-
bound and soluble molecules. Right: Components of the endothelial
glycocalyx. Bound to the endothelial membrane are proteoglycans,
with long unbranched glycosaminoglycan side-chains (GAG-chain)
and glycoproteins, with short branched carbohydrate side-chains.
Incorporated in and on top of this grid are plasma and endothelium-
derived soluble components, including hyaluronic acid and other
soluble proteoglycans (e.g., thrombomodulin) and various proteins,
such as extracellular superoxide dismutase (ec-SOD) and antithrombin
III (AT III). Together, these components form the endothelial
glycocalyx that functions as a barrier between blood plasma and the
endothelium and exerts various roles in plasma and vessel wall
homeostasis. Note that this figure is not drawn to scale; its purpose is
to illustrate glycocalyx composition
Table 1 Characteristics of proteoglycan core proteins in the vascular endothelial glycocalyx
Core protein
group
Core protein size
(kDa)
Number of
subtypes
Number of GAG-chains
linked
Type of GAG-chains
linked
Structural relation
to cell membrane
Syndecan 19–35 4 5 HS/CS Membrane-spanning
Glypican 57–69 6 3 HS/CS GPI-anchor
Perlecan 400 1 3 HS/CS Secreted
Versican 370 1 10–30 CS/DS Secreted
Decorin 40 1 1 CS/DS Secreted
Biglycan 40 1 2 CS/DS Secreted
Mimecan 35 1 2–3 KS Secreted
GAG Glycosaminoglycan, HS heparan sulfate, CS chondroitin sulfate, DS dermatan sulfate, KS keratan sulfate, GPI glycosylphosphatidylinositol
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bility is that hyaluronan is (in part) not directly bound to the
membrane at all. It is capable of forming strikingly viscous
solutions [57]. More recently, intracellular hyaluronan
binding proteins such as cdc37 [31]a n dP 3 2[ 15] have been
identified, suggesting a role for this glycosaminoglycan
within the cell [23, 58].
Heparan sulfate and chondroitin sulfate/dermatan sulfate
containing proteoglycans are produced in the endoplasmic
reticulum and Golgi apparatus of the endothelial cell. After
the ribosomal translation of the core protein, a xylosyltrans-
ferase will transfer xylose (Xyl) from uracildiphosphate
xylose to specific serine residues (Ser) in the core protein.
The xylose-enriched core protein is transported to the cis-
Golgi, and galactosyltransferases types I and II will add
two galactose-groups (Gal) to the xylose, after which glucu-
ronosyltransferase type I adds glucuronic acid, thus, com-
pleting the primary linker for glycosaminoglycan chains:
–GlcA–β3–Gal–β3–Gal–β4–Xylβ3–[Ser].
After formation of the primary linker, the following step
determines the type of glycosaminoglycan chain that will
be formed. In the case of heparan sulfate, an α4-glucos-
amine is added; in the case of chondroitin sulfate and
dermatan sulfate, a β4-galactosamine is added, and both
galactose-residues from the linker may be sulfated. From
this point onward, glucuronic acids and glucosamines are
linked to the core protein. After chain polymerization, the
growing glycosaminoglycan chain will undergo modifica-
tions including N-sulfation, O-sulfation, and epimerization.
The latter changes glucuronic acid residues into iduronic
acid residues and will change any chondroitin sulfate chain
into its type B dermatan sulfate. These chain modifications
take place in both the cis- and the trans-Golgi, determining
the final type and functionality of the proteoglycan and each
of its side chains. In contrast, hyaluronan is assembled at the
cytosolic side of the cell membrane, and it is not modified
afterwards. As a consequence, it has no sulfate groups or
modification pattern.
As glycosaminoglycan chains contain numerous specific
binding sites for plasma-derived proteins, small chain
modifications can have great functional consequences.
Sequential enzymatic modifications of the individual saccha-
ride units within glycosaminoglycan chains endow proteo-
glycans with unique functions. Typically 16–48 different
sulfation patterns may exist per disaccharide and as functional
domains are assumed to be usually penta- to deca-saccharide
long, at least 16
3=4,096 different sulfation patterns on a
hexasaccharide backbone are theoretically possible, and such
a structural diversity corresponds to diversified biological
functions of glycosaminoglycans. Indeed, it has been shown
that modification patterns vary in time and under different
(patho)physiological stimuli [4, 131]. The diversity of
glycosaminoglycan sulfation patterns and its effect on
specific protein binding and modulation of protein function
suggest that conditions that diminish glycocalyx thickness or
modulate protein specific glycosaminoglycan sulfation pat-
terns and charge are likely to modulate vascular permeability
and alter specific protein binding and activity.
Glycoproteins
Besides the proteoglycans with their long linear side chains,
certain glycoproteins are also regarded as “backbone”
molecules, connecting the glycocalyx to the endothelial
cell membrane. This group of endothelial glycoproteins,
characterized by relatively small (2–15 sugar residues) and
branched carbohydrate side chains, comprises a number of
molecules that all have been studied intensively; major
classes that will be discussed in more detail below are the
endothelial cell adhesion molecules and components of the
coagulation and fibrinolysis system. It is beyond the scope
of this review to categorically discuss all glycoproteins that
can be expressed by endothelial cells. Furthermore, one
should realize that the level of glycoprotein expression on
the endothelial cell membrane varies considerably with cell
activation or stimulation.
Table 2 Composition of the disaccharides of various glycosaminoglycan chains
Heparan sulfate Chondroitin sulfate Dermatan sulfate
a Hyaluronan Keratan sulfate
Uronic acid GlcA(2S) IdoA(2S) GlcA GlcA IdoA(2S) GlcA Gal(6S)
Disaccharide link 1β41 β31 β31 β31 β4
Hexosamine GlcNAc(NS)(3S)(6S) GalNAc4S
a GalNAc6S
a GalNAc(4S)(6S) GlcNAc GlcNAc(6S)
Polymerization link 1β41 β41 β41 β41 β3
Note the various possibilities of sulfation in heparan sulfate. These may coincide (e.g., in heparan sulfate the hexosamine GlcNS3S). A rare but
possible hexosamine in heparan sulfate is the N-unsubstituted glucosamine GlcNHþ
3

; which has been left out of the table for convenient
reading. Also note the presence of IdoA in dermatan sulfate, in contrast to the other chondroitin sulfates, making it more alike to heparan sulfate.
GlcA Glucuronic acid, IdoA iduronic acid, Gal galacturonic acid, GlcNAc N-acetyl-glucosamine, GalNAc N-acetyl-galactosamine, 2S 2-O-
sulfated, 3S 3-O-sulfated, 4S 4-O-sulfated, 6S 6-O-sulfated, NS N-sulfated
aThere are three types of chondroitin sulfate. Type A only has 4-O-sulfated N-acetyl-galactosamines, type B is known as dermatan sulfate and
type C only has 6-O-sulfated N-acetyl-galactosamines.
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glycoproteins that play a major role in cell recruitment from
the bloodstream and in cell signaling. The three families of
cell adhesion molecules present in the endothelial glyco-
calyx are the selectin family, the integrin family, and the
immunoglobulin superfamily.
Glycoproteins from the selectin family contain a cyto-
plasmic tail, a transmembrane domain, several consensus
repeats, an epidermal growth factor-like domain, and a
terminal lectin domain, which is primarily responsible for
binding of carbohydrate groups on glycosylated proteins or
lipids. However, the epidermal growth factor-like domain is
involved in selectin-ligand recognition as well [29, 48].
Selectins found on the vascular endothelium are E-selectin
and P-selectin, both involved in leukocyte–endothelial cell
interactions [108]. P-selectin is constitutively produced and
subsequently stored in the Weibel–Palade bodies of the
endothelial cells. Exocytosis of Weibel–Palade bodies as
induced by stimuli such as thrombin and histamine allows a
rapid translocation of P-selectin to the cell surface [19, 53].
However, this expression is short-lived due to P-selectin
internalization and redirection to lysosomal granules or the
Golgi apparatus, where it is restored in newly formed
Weibel–Palade bodies [109]. E-selectin is not stored in
granules, but requires de novo mRNA and protein synthesis
to be expressed on the cell surface. Stimulation of endothelial
cells by cytokines such as interleukin-1, tumor necrosis factor
α, and lipopolysaccharide upregulates E-selectin expression;
this typically requires 2–6h[ 47]. In some tissues like the
skin, P- and E-selectin appear to be constitutively expressed
on endothelial cells [78, 139].
Integrins are heterodimeric molecules, composed of
non-covalently bound α and β subunits. Both subunits
have a cytoplasmic tail and a transmembrane domain, and
together, they constitute an integral membrane protein. To
date, 18 different α-subunits and 8 β-subunits have been
identified, which means that each integrin is characterized
by the specific combination of its subunits [142]. Integrins
are found on many cell types, including endothelial cells,
leukocytes, and platelets. In their luminal membrane,
endothelial cells express integrin αVβ3, which is an
important mediator of platelet–endothelial cell interactions
[11]. Most other endothelial cell integrins are involved in
binding to the basement membrane. These integrins, such as
α2β1, α5β1,a n dα6β1, bind to multiple extracellular matrix
ligands, and are as such, responsible for interactions with
laminin, fibronectin, and collagen. Many studies have focused
and still focus on the interactions between these integrins and
the subendothelial matrix during angiogenesis [98].
The immunoglobulin superfamily of glycoproteins is
characterized by a cytoplasmic tail, a transmembrane
domain, and a variable number of immunoglobulin-like
domains that protrude luminally. Best known examples are
intercellular adhesion molecule 1 and 2 (ICAM-1 and -2),
vascular cell adhesion molecule 1 (VCAM-1), and platelet/
endothelial cell adhesion molecule 1 (PECAM-1), which act
as ligand for integrins on leukocytes and platelets and are
crucial mediators of leukocyte homing to the endothelium
and subsequent diapedesis. ICAM-1 and -2 and PECAM-1
have a baseline expression, whereas VCAM-1 is only
present after endothelial cell stimulation by cytokines, which
also upregulates ICAM-1 expression [71]. Paradoxically, the
constitutive expression of PECAM-1 is decreased after
cytokine treatment [113]. The role of ICAM-2 in inflamma-
tion is still unclear, as it is also downregulated by inflam-
matory stimuli. Recently, it was shown that ICAM-2 is
involved in regulation of angiogenesis [41].
Besides the cell adhesion molecules, the endothelial
glycocalyx harbors glycoproteins with functionality in
coagulation, fibrinolysis, and hemostasis. A good example
is the glycoprotein Ib-IX–V complex, which is expressed on
endothelial cells and also on platelets. It consists of four
glycoproteins: Ibα,I b β, IX, and V, that are each membrane-
spanning polypeptides. Glycoprotein Ibα and Ibβ are
covalently linked via a disulfide group, whereas IX and V
are non-covalently attached to the Ib heterodimer. The
Ib-IX–V complex binds von Willebrand factor (vWf) and
is primarily known as the platelet vWf-receptor [65, 99].
Furthermore, the complex also binds P-selectin, mediating
the interaction of platelets with activated endothelial cells
[7]. Like platelets, endothelial cells express all components
of the Ib-IX–Vc o m p l e x[ 115, 141], which on one hand,
allows binding to the vWf substrate of the subendothelium,
and on the other, binds Weibel–Palade body derived vWf,
secreted luminally by activated endothelial cells.
Soluble components
Embedded within and layered on top of the mesh of
proteoglycans and glycoproteins are soluble components of
various types such as proteins and soluble proteoglycans.
These components are either derived from the endothelium
or from the bloodstream, such as albumin and orosomucoid,
which are pivotal in preserving the (charge-)selectivity of the
permeability barrier [42]. The soluble components of the
glycocalyx contribute greatly to the functional importance of
the glycocalyx, as will be described below. The structural
attribution of these soluble components is less well estab-
lished. At least some of the soluble components may
contribute to the structural organization of the luminal glyco-
calyx, although this is hard to prove. There are indications
that proteoglycans bind to each other and to proteins [54,
88]. Protein–glycosaminoglycan–protein complexes have
been identified, although not in the glycocalyx in particular
[145]. Still, it is presumable that interactions between
membrane-bound proteoglycans, soluble proteins, and solu-
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some stability to the luminal glycocalyx. Hyaluronan might
play an important role in this respect, being a very large
linear molecule and possibly unbound to the endothelial cell
membrane (Fig. 1). It has been shown to interact with itself,
forming stable hyaluronan–hyaluronan complexes [103,
104]. Still, the glycocalyx is a delicate layer, and removal
of one specific component may result in loss of function of
the total [117].
Functional importance
The endothelial glycocalyx as the endothelial gatekeeper
Located between the blood stream and the endothelium, the
endothelial glycocalyx is an important determinant of
vascular permeability [35, 130]. It is able to limit access
of certain molecules to the endothelial cell membrane, as
has been demonstrated in small rat mesenteric arteries with
the use of fluorescently labeled dextrans of various
molecular weights, showing increasing permeability for
smaller molecules [125]. Enzymatic (partial) removal and
subsequent loss of permeability barrier function of the
glycocalyx in rat myocardial capillaries leads to myocardial
edema [124]. Not only size and steric hindrance play a role
in glycocalyx dependent permeability, but also, electrostatic
charges of the glycocalyx and the permeating substance.
With many of the glycosaminoglycan chains being highly
sulfated, the glycocalyx presents a net negatively charged
surface to the bloodstream. Accordingly, neutralization of
the glycocalyx induces an increase in albumin uptake by
cultured endothelial cells [121] and an increased perme-
ability for fluorescently labeled dextrans in rat mesenteric
arteries [126].
The classical model used to describe microvascular fluid
exchange is that of Starling [112], stating that fluid
filtration rate across capillary endothelium is determined
by the hydraulic and colloid osmotic pressures in the
vascular lumen and in the surrounding tissue. This balance
has been applied across the entire transendothelial barrier,
with the different pressures being assessed globally. The
discovery of a relatively thick endothelial glycocalyx and
its influence on, e.g., edema formation has led to a major
revision of the Starling principle by Weinbaum [137] and
Michel [68], who proposed to apply the pressure gradients
to the endothelial glycocalyx only. Hu and Weinbaum used
this idea to generate a 3-D model of permeability over
different regions of the endothelial layer, such as the
glycocalyx, the endothelial clefts, and the tight junctions
[40]. Recently, this model was simplified into a 1-D
description of the varying tissue concentration gradients
and subsequent permeability of the endothelium [144].
Another model, known as the glycocalyx-junction-break
model, applies the Starling mechanism over the glycocalyx
and describes its effects on solute and water transport over
the endothelium, based on theoretical “pores” in the
endothelium [79]. Recently, Curry has written a review on
this model and the influences of phenotypical changes on
microvascular permeability [14]. The importance of the
endothelial glycocalyx in controlling extravasation of
colloids and fluids is also stressed by studies of Rehm et
al. [91]a n dJ a c o be ta l .[ 45], who show impaired
endothelial barrier function after glycocalyx degradation
in an isolated, perfused heart model. Infusion of 5%
albumin or 6% hydroxethyl starch, a natural and an
artificial colloid, led to decreased fluid extravasation.
However, after 20 mins of warm ischemia, only albumin
infusion prevented vascular leakage. This underscores the
importance of an intact glycocalyx and the role of plasma-
derived proteins for competent glycocalyx functioning. The
revised Starling principle has provided more detailed
insight into vascular permeability and stresses the impor-
tance of the endothelial glycocalyx as a major determinant.
Besides its capacity to restrict molecules from reaching
the endothelium, the glycocalyx also influences blood
cell–vessel wall interactions. It repulses red blood cells
from the endothelium. In the microcirculation, a red blood
cell exclusion zone flanking the endothelium can be
observed in vivo, which is decreased upon light dye-
induced breakdown of the glycocalyx [129]. Similarly,
platelets are not often observed interacting with the
endothelium in control conditions, whereas partial glyco-
calyx removal by infusion with oxidized low-density
lipoprotein (ox-LDL) is accompanied by an increase in
platelet–vessel wall interactions [128]. The role of the
glycocalyx in leukocyte–vessel wall interactions seems
dual: on the one hand, it harbors the endothelial cell
adhesion molecules, such as P-selectin, ICAM-1, and
VCAM-1; on the other hand, it attenuates adhesion of
leukocytes to these molecules.
In healthy mouse cremaster muscle venules, breakdown
of heparan sulfate side chains through heparitinase leads to
an increase in leukocyte adhesion to the endothelium in a
dose-dependent manner [13]. Administration of ox-LDL or
TNFα also induces leukocyte rolling and adhesion [13, 36].
Steric hindrance seems to play a role in this process. The
endothelial glycocalyx is much thicker (ranging from 0.2–
0.5 μmi nc a p i l l a r i e s[ 124]t o2 –3 μm in small arteries [125]
and 4.5 μm in carotid arteries [67]) than the length of the
various cell adhesion molecules. P-selectin, for example, the
molecule initiating leukocyte rolling, only extends about
38 nm from the endothelial surface [111]. On cultured cells
transfected with P-selectin constructs with two to six
consensus repeats that are consequently shorter than normal
P-selectin (nine consensus repeats), the number of attaching
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Cells defective of glycosylation, having a thinner glycoca-
lyx, showed increased attachment of neutrophils [81].
Hence, in normal conditions, the glycosaminoglycan chains
and soluble components of the glycocalyx seem to shield
adhesion molecules, thereby, preventing interaction. Stimuli
which degrade the glycocalyx or induce a more open mesh,
such as enzymes, cytokines, or ischemia and reperfusion,
appear to uncover the adhesion molecules, which in turn,
allows blood cells to interact with the endothelium [13, 36,
70, 128]. One should realize that ligands for endothelial
adhesion molecules are not uniformly distributed over the
cell membrane of leukocytes, but show association with
microvilli and membrane ruffles [102]. As the glycocalyx is
estimated to have a low stiffness [33, 106, 138], it is likely
that the ligand bearing leukocyte membrane extensions
protrude relatively easily into the glycocalyx to reach their
receptor and enable leukocyte–vessel wall interaction. In
contrast to other tissues, leukocyte–vessel wall interactions
occur spontaneously in venules in the skin, even in normal
conditions without preceding trauma or inflammation [46,
78]. Whether this is associated with a deviating glycocalyx
structure and/or composition in skin microvessels remains to
be elucidated.
The presence of a relatively thick endothelial glycocalyx
in vivo has great consequences for rheology, especially in
the microvasculature [62, 84]. In this part of the circulation,
local blood viscosity and hematocrit appear to be modulated
by the glycocalyx. Using a physical model, based on hemo-
dynamic and hematocrit measurements in microvascular
networks in vivo, Pries and Secomb recently demonstrated
that incorporation of realistic estimates of glycocalyx
dimensions in reconstructed mesenteric microvascular net-
works introduces about a twofold increase in the apparent
viscosity of blood. These changes are sufficient to minimize
discrepancies between experimentally determined and theo-
retically predicted microvascular network resistances in
previous studies, which were based on the apparent viscosity
of blood in glycocalyx-devoid glass capillaries [85].
The endothelial glycocalyx as mechanotransducer
The endothelium is exposed to mechanical forces induced
by blood flow. It has long been recognized that these forces,
in particular, shear stress, determine endothelial cell
morphology and function [16, 18]. Endothelial cells
exposed to shear stress produce nitric oxide (NO) [96],
which is an important determinant of vascular tone. How-
ever, the molecule(s) responsible for the translation of
biomechanical forces into biochemical signals (mechano-
transduction) have not been identified as yet. Recently, the
glycocalyx has been added to the list of possible candidates.
In studies with cultured endothelial cells, Florian and
colleagues [24] showed that treatment with heparitinase to
specifically break down heparan sulfate glycosaminogly-
cans results in inadequate responses to shear variations and
impaired NO production. Similarly, ex vivo experiments on
canine femoral arteries conducted by Mochizuki and co-
workers exhibited reduced shear-induced NO production
after infusion with hyaluronidase, which degrades the
hyaluronan glycosaminoglycans in the glycocalyx [69].
Thus, both heparan sulfate and hyaluronan appear to play a
role in detecting and amplifying flow-induced shear forces
[69].
Interestingly, exposure of human umbilical vein endothe-
lial cells to shear stress was found to increase the amount of
hyaluronan in the glycocalyx approximately twofold, which
may represent a positive feedback for shear stress sensing by
endothelial cells [30]. Another recent study showed a
correlation between shear stress profile and glycocalyx
dimensions in the mouse carotid artery; the laminar flow
profiles in the common carotid were found to coincide with a
glycocalyx thickness of 399±174 nm, whereas disturbed
laminar flow in the sinus region of the carotid bifurcation
coincided with a thinner glycocalyx of 73±36 nm [123].
Moreover, the flow divider region of the carotid bifurcation,
supposedly having an undisturbed high laminar flow profile,
was covered with a glycocalyx of 308±185 nm, comparable
to the common carotid glycocalyx thickness.
From these data, it seems likely that the glycocalyx plays
an important role in mechanotransduction and that its
composition is, in turn (at least partly), shear-dependent.
The different components of the glycocalyx probably operate
together, which means that the glycocalyx, as a whole, is
responsible for its role as mechanotransducer. This idea is
confirmed by theoretical models based on a regular
hexagonal distribution of core proteins over the endothelial
cell membrane [138]. Recently, Tarbell and Pahakis
reviewed the current concepts on mechanotransduction by
the (membrane-bound) glycocalyx [116]. They conclude that
the glycocalyx core proteins are responsible for transmission
of shear stress signals into specific cell signaling processes,
e.g., NO production and cytoskeletal reorganization. At the
same time, shear stress is transmitted to other regions of the
endothelial cell as well, such as intercellular junctions and
basal adhesion plaques, which are responsible for additional
shear sensing even in the absence of a glycocalyx.
The endothelial glycocalyx as control center
for the microenvironment
The proteoglycans in the glycocalyx contribute greatly to
its functional importance. The glycosaminoglycan chain
variety arising from chain epimerization, elongation, and
most notably, chain sulfation, gives rise to a heterogeneous
surface to which a lot of plasma-derived molecules can
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interaction with the glycocalyx for their functionality.
Docking of plasma-derived molecules can influence the
local environment in several ways: (1) Binding of receptors
or enzymes and their ligands to the endothelial glycocalyx
causes a localized rise in concentration of these substances,
which enables proper signaling or enzymatic modification.
Fibroblast growth factor (FGF) signaling is mediated in this
way and is known to depend completely on the interaction of
both ligand and receptor with the glycocalyx [3, 26].
Similarly, the glycocalyx is involved in the lipolytic system,
binding both lipoprotein lipase and its ligand low-density
lipoprotein (LDL) [133, 140]. (2) Binding of plasma-derived
molecules to the glycocalyx can lead to a local concentration
gradient, which is often seen in growth factor-regulated gene
transcription and developmental processes [61, 82]. (3)
Docking of enzymes and their agonists or inhibitors to the
glycocalyx adds a vasculoprotective role to glycocalyx
functionality. Several important anticoagulant mediators can
bind to the glycocalyx, such as antithrombin III, heparin
cofactor II, thrombomodulin, and tissue factor pathway
inhibitor (TFPI). Antithrombin III is a strong inhibitor of
procoagulant enzymes like thrombin and activated factors X
and IX (FXa and FIXa) [87]. It is known to bind to specific
regions in heparan sulfate, which enhances its anticoagulant
activity [107]. Heparin cofactor II is a thrombin-specific
protease inhibitor [80], which is activated by dermatan
sulfate in the glycocalyx [120]. Thrombomodulin is a
chondroitin sulfate containing protein expressed by endothe-
lial cells and is able to convert thrombin from a procoagulant
enzyme to an activator of the protein C pathway, thus,
becoming anticoagulant [136]. TFPI is a potent inhibitor of
FVIIa and FXa. TFPI is believed to bind to the glycocalyx
via heparan sulfates, but other proteins could be involved as
well [49]. Furthermore, uptake and degradation of TFPI–
FXa complexes depends on heparan sulfates in the glyco-
calyx [38]. All these anticoagulant molecules present in the
glycocalyx contribute to the thromboresistant nature of
healthy endothelium [21]. The endothelial glycocalyx also
modulates inflammatory responses by binding cytokines and
attenuating binding of cytokines to cell surface receptors.
Shedding of heparan sulfate from the glycocalyx results in
increased endothelial cell sensitivity to activation by cyto-
kines [9, 10]. Another aspect of the vasculoprotective role of
the endothelial glycocalyx is its capacity to bind quenchers
of oxygen radicals, such as extracellular superoxide dis-
mutase (SOD) [59]. These enzymes help to reduce the
oxidative stress and keep up NO bioavailability, thus,
preventing the endothelium from becoming dysfunctional.
The endothelial glycocalyx in pathophysiology
In healthy vessels, the endothelial glycocalyx determines
vascular permeability, attenuates blood cell–vessel wall
interactions, mediates shear stress sensing, enables balanced
signaling, and fulfills a vasculoprotective role. But when it
is disrupted or modified, these properties are lost, as has
been shown through direct targeting of the glycocalyx in
experimental settings. In the last few years, evidence is
emerging that (damage to) the glycocalyx plays a pivotal
role in several vascular pathologies. Here, we will discuss
its suspected roles in diabetes, ischemia/reperfusion, and
atherosclerosis.
Diabetes
Diabetes is a clinically well-known disease with far-reaching
complications, such as retino- and nephropathy, and elevated
Table 3 Molecules dependent on interaction with the endothelial glycocalyx for proper functioning
Interacting molecule Primary function in vasculature Reference number
Antithrombin III Potent inactivator of pro-coagulant proteases such as thrombin, factor Xa
and factor IXa; activity enhanced by heparin or heparan sulfate
107
Heparin cofactor II Inactivator of the procoagulant protease thrombin; activated by dermatan sulfate in the
endothelial glycocalyx
120
TFPI Anticoagulant protein blocking activated factor VII and X 38, 49
LPL Enzyme involved in breakdown of low density lipoproteins 133
LDL Transports cholesterol and triglycerides through the circulation 140
VEGF Potent stimulator of angiogenesis, production of which is triggered by hypoxia 92
TGFβ1/2 Growth factor known to mediate in a lot of signaling pathways, including smooth
muscle cell differentiation and vascular tone and reactivity
64
FGF(r) Growth factor (receptor) involved in endothelial cell proliferation and angiogenesis 3, 26
Ec-SOD Extracellular quencher of reactive oxygen species 11
IL 2, 3, 4, 5, 7, 8, 12, RANTES Chemotaxis of leukocytes to the subendothelium; involved in arrest and diapedesis 2, 39, 100, 110, 143
TFPI Tissue factor pathway inhibitor, LPL lipoprotein lipase, LDL low density lipoprotein, VEGF vascular endothelial growth factor, TGFβ1/2
transforming growth factor β1o rβ2, FGF(r) fibroblast growth factor (receptor), ec-SOD extracellular superoxide dismutase, IL interleukin,
RANTES Regulated on Activation, Normal T Expressed and Secreted—also known as chemokine CCL5
352 Pflugers Arch - Eur J Physiol (2007) 454:345–359risks for atherothrombotic cardiovascular events. One of the
hallmarks of diabetes is insulin absence or resistance and
subsequent hyperglycemia, impairing the protective capacity
of the vessel wall [73], and resulting in enhanced endothelial
permeability [1] and impaired NO synthase function [20].
However, a common pathway leading to these vascular
dysfunctions has not been identified. Recently, it was shown
that the systemic glycocalyx volume of healthy volunteers,
as assessed by comparing the intravascular distribution
volume of a glycocalyx-permeable and a glycocalyx-
impermeable tracer, was halved within 6 h after induction
of acute hyperglycemia [76]. Using the same methodology,
the systemic glycocalyx volume in type 1 diabetics was
found to be about half of that of healthy controls; it was
further reduced in diabetics with microalbuminuria [75]. In
the same study, plasma levels of hyaluronan and hyaluron-
idase were found to be elevated in patients with diabetes,
reflecting increased synthesis and shedding of hyaluronan
under hyperglycemic conditions. Both studies show that
acute and long-standing hyperglycemia is associated with
profound reduction of glycocalyx dimensions. It is tempting
to speculate that this damage to the glycocalyx contributes to
endothelial dysfunction in hyperglycemic conditions, which
can be measured in nondiabetic subjects as well [118].
Further studies are needed to investigate whether glycocalyx
perturbation is responsible for the (micro)vascular compli-
cations in diabetes.
Ischemia/reperfusion
Damage to tissues during a period of absent or decreased
flow (total or partial ischemia) can paradoxically be
exaggerated by restoration of blood flow (reperfusion).
Although the severity of damage resulting from ischemia/
reperfusion varies between tissues, a common component
of this pathologic process for all organs is microvascular
dysfunction [32, 105]. Endothelial cells play a central role
and exhibit swelling and detachment from the basement
membrane after ischemia/reperfusion [77]. Especially in
postcapillary venules, endothelial cells suffer from in-
creased oxidative stress [56], leukocytes adhere and
transmigrate [8, 132], and vascular permeability increases
[55]. These endothelial consequences of ischemia/reperfu-
sion allude at involvement of the endothelial glycocalyx.
Indeed, it was recently shown by Mulivor and Lipowsky
[70] that intestinal ischemia/reperfusion led to significant
reduction of glycocalyx thickness in rat mesenteric venules,
most likely due to shedding of glycosaminoglycan chains.
The effects of ischemia/reperfusion on the glycocalyx could
be attenuated by blockade of xanthine-oxidoreductase,
which is an endogenous reactive oxygen species (ROS)
producing enzyme bound to heparan sulfate domains in the
glycocalyx. This way, a central role for ROS in disruption
and shedding of the glycocalyx in ischemia/reperfusion was
established [97]. Infusion of exogenous hyaluronan to
restore the glycocalyx or administration of pertussis toxin,
which inhibits G-protein-mediated shedding of glycosami-
noglycan chains, also reduced ischemia-/reperfusion-in-
duced damage [70]. Together, these data hint at a role for
the endothelial glycocalyx in the pathophysiology of
ischemia-/reperfusion-induced tissue damage. However, its
relative contribution to this process and the impact of
possible therapeutical interventions are yet to be established
[6, 122, 134].
Atherosclerosis
Atherosclerosis is a large artery disease and typically
requires high plasma levels of LDL to develop at predilec-
tion sites [34] that are marked by disturbed flow profiles.
Subendothelial retention of atherogenic lipoproteins and
subsequent inflammatory responses lead to the formation of
subendothelial plaques [60, 93]. The role of the endothelial
glycocalyx in atherogenesis is, as yet, not well-established,
but there are some interesting observations which point at its
involvement.
In 2000, Vink and colleagues [128] showed that
administration of clinically relevant doses of ox-LDL leads
to a disruption of the glycocalyx in hamster cremaster
muscle microcirculation and evokes local platelet adhesion.
Co-infusion with SOD and catalase, enzymes catalyzing the
dismutation of superoxide anion and the decomposition of
hydrogen peroxide, abolished this effect of ox-LDL,
implicating a role for oxygen-derived free radicals. Indeed,
loss of glycocalyx results in shedding of endogenous
protective enzymes, such as extracellular SOD, and
increases the oxidative stress on endothelial cells. This
was further illustrated by a recent study by van den Berg et
al. [123], showing a reduction in glycocalyx dimensions
due to a high-fat, high-cholesterol diet. Furthermore, an
inverse relation between glycocalyx thickness and intima–
media ratio was found, reflecting a reduction of vasculo-
protective capacity of the endothelial glycocalyx at sites
with higher atherogenic risk. In healthy mice, regional
variations were found showing a thinner glycocalyx in the
internal carotid sinus region compared to the common
carotid artery. Together, these data suggest that the
endothelial glycocalyx is involved in the initiation and
progression of the atherosclerotic process [74].
In summary, the endothelial glycocalyx appears to be
perturbed in several vascular diseases. It remains to be
elucidated whether glycocalyx perturbation is causally
involved in the pathophysiology of these diseases. If so,
restoration of the glycocalyx may be a therapeutic target of
interest. Furthermore, identification of specific glycosami-
noglycan domains involved in these diseases, as a platform
Pflugers Arch - Eur J Physiol (2007) 454:345–359 353for other substances or signaling pathways, might also
prove to be of therapeutic value [4].
Visualization techniques
Because of the functional importance of the endothelial
glycocalyx, development of direct visualization techniques is
crucial to establish its exact role. The glycocalyx can be
labeled by administration of specific markers that attach to
one or more of its components, making them fluorescent or
detectable. Preparation of (parts of) the vessel would then
allow specific microscopic imaging of the endothelial
glycocalyx. Regretfully, the glycocalyx is very vulnerable
and easily disturbed or dehydrated during vessel handling
and preparation protocols. As a result, glycocalyx dimen-
sions are easily underestimated, which is illustrated by the
first images of the glycocalyx, made by transmission electron
microscopy (TEM) in 1966 with the use of the probe
ruthenium red; glycocalyx thickness measured this way
approximated 20 nm in capillaries [66]. Since then, many
other attempts were made to image the glycocalyx using
TEM. On bovine aorta endothelial cells under shear stress
conditions of 3.0 Pa, the glycocalyx was reported to be
40 nm thick [121]. These dimensions did not comply with
theoretical estimates predicting the glycocalyx to be up to
1 μmt h i c k[ 51]. Using a new staining protocol with Alcian
blue 8GX, van den Berg et al. [124] recently applied TEM to
measure endothelial glycocalyx dimensions in rat myocardial
capillaries, which revealed that endothelial cells are covered
by a 200- to 500-nm thick glycocalyx (Fig. 2a). Hyaluron-
idase treatment before fixation and staining resulted in
significant reduction of this layer to 100–200 nm. The
groups of Haraldsson [37] and of Rostgaard and Qvortrup
[94, 95] improved the TEM staining protocol using fluo-
rocarbon-based oxygen carrying fixatives, revealing glyco-
calyces as thick as 60–200 nm in glomerular capillaries, and
50–100 nm in intestinal fenestrated capillaries. Apparently,
the new staining and preparation protocols improved glyco-
calyx conservation in TEM experiments. However, TEM
cannot be used in the in vivo situation.
Some 30 years after the first TEM images were made,
Vink et al. [129] used intravital microscopy to visualize the
endothelial glycocalyx in hamster cremaster muscle capillar-
ies in vivo using indirect approaches. The glycocalyx was
recognized as a red blood cell “exclusion zone” or “gap”
between the flowing red blood cells and the endothelium. In
addition, the plasma was labeled by a fluorescent dextran,
and the glycocalyx then appeared as a plasma exclusion zone
(Fig. 2b). Interestingly, no exclusion zone was found for
rolling white blood cells, suggesting that they have the
ability to compress the glycocalyx in these vessels, which
complies with the estimated low stiffness of the glycocalyx
[33, 106, 138]. Subtraction of the diameter of the plasma
column from the anatomical internal diameter revealed the
dimensions of the glycocalyx, which appeared to be 0.4–
0.5 μmt h i c k[ 129]. This method has been used in many
studies since, primarily in the cremaster muscle microcircu-
lation of hamsters [35, 36, 130]o rm i c e[ 13, 97]. This tissue
is suited for intravital microscopy because it is thin and
translucent, allowing clear visualization of microvascular
endothelial cells and flowing blood cells, with low or absent
vessel wall motion (Fig. 2b). In addition, local flow
velocities can be measured. However, the estimation of the
glycocalyx thickness using intravital microscopy-based
methods is indirect. Furthermore, intravital microscopy
Fig. 2 Visualization of the endothelial glycocalyx with different
microscopic techniques. a Endothelial glycocalyx of a rat left
ventricular myocardial capillary stained with Alcian blue 8GX and
visualized using electron microscopy. Bar represents 1 μm. Repro-
duced with permission from reference number [124]. b Intravital
microscopic recording of the endothelial glycocalyx of a hamster
cremaster muscle capillary. The anatomical diameter of 5.4 μmi s
larger than the red blood cell column width (left pane) or the plasma
column width (right pane) labeled with fluorescent dextran (70 kD).
This difference is caused by the presence of the endothelial
glycocalyx. The bar in the left pane represents 5 μm. Reproduced
with permission from reference number [129]. c Endothelial glyco-
calyx of a mouse common carotid artery. 3D-reconstruction of a series
of optical slices obtained with two-photon laser scanning microscopy
showing part of the vessel wall. The intact vessel was perfused with
FITC-labeled lectin (WGA) to stain the endothelial glycocalyx (green)
and SYTO 41 to label cell nuclei (blue). The arrows indicate the
direction of the X, Y, and Z axis. The scanned volume approximates
200×200×60 μm
3. For details on methodology see also reference
number [67]
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larger vessels.
Direct visualization of the glycocalyx has been per-
formed via several approaches, mostly using lectins which
are proteins that bind specific disaccharide moieties of
glycosaminoglycan chains [5, 24, 70]. Other labels include
antibodies for heparan sulfate, syndecan-1 or hyaluronan
[24, 70]. When attaching these markers to a fluorescent
probe, advanced microscopic techniques can be applied to
visualize the glycocalyx. Confocal laser scanning micros-
copy (CLSM) enables optical sectioning with good optical
resolution, allowing 3D reconstructions of the specimen.
Lectin labeling of the glycocalyx of cultured human
umbilical vein endothelial cells and subsequent CLSM
imaging revealed a surface layer as thick as 2.5±0.5 μm
[5]. CLSM has also been used to detect concentration
changes of fluorescently labeled lectins in the glycocalyx of
fixated rat mesentery postcapillary venules in case of
ischemia/reperfusion and inflammation [70]. Because larger
vessels have thicker walls, which results in lower light
penetration depths with significant loss of resolution at
higher depths (>40 μm) [127] due to increased scattering of
signal, CLSM is less suitable for imaging of the glycocalyx
in arteries.
A promising technique to directly visualize the glycocalyx
in larger vessels, both ex vivo and in vivo, is two-photon
laser scanning microscopy (TPLSM). TPLSM depends on
excitation of a fluorophore by simultaneous uptake (i.e.,
within 10
−18 s) of two red photons, instead of one blue
photon as in conventional fluorescence excitation. The use of
long wavelength red photons reduces scattering, and hence,
increases penetration depth into tissue. Excitation of the
fluorophore and consequent fluorescence only occurs at the
focal point of the illumination cone, as the probability of
two-photon excitation depends on the squared intensity of
the excitatory photons. Any light received by the photo-
multipliers has to originate from the focal position, so
scattering of the emitted photons does not influence
resolution and no pinholes are required. As a consequence,
TPLSM offers good resolution and optical sectioning at
reasonable acquisition speed, while bleaching and phototox-
icity of the dyes is limited to the focal position. The
combination of enhanced penetration depth, good resolution,
optical sectioning, and low phototoxicity makes TPLSM a
suitable technique to visualize the delicate endothelial
glycocalyx in larger vessels. This idea was confirmed by a
recent study by Megens and colleagues [67] in which the
endothelial glycocalyx was imaged with TPLSM in intact
mouse carotid arteries (Fig. 2c); the glycocalyx thickness
was found to be 4.5±1.0 μm. As TPLSM is also applicable
in vivo in rodents [127], it might prove to be a good
approach of in vivo visualization of the glycocalyx in the
macrocirculation of these animals.
Conclusions
Overlying the vascular endothelium, the glycocalyx is a
membrane-bound mesh in which plasma-derived molecules
integrate. It exerts a variety of functions, important in normal
vascular physiology and also in vascular disease. Although
data from experiments in microcirculation, and more
recently, in macrocirculation strongly suggests a vasculopro-
tective role for the glycocalyx, research on this subject is
hampered by lack of a good visualization technique. Two-
photon laser scanning microscopy may prove to be a
successful tool in achieving direct visualization of the
glycocalyx in larger arteries in rodents, both ex vivo and in
vivo, with the possibility to analyze focal variations in the
composition or integrity of this layer.
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